Syngene International Limited is a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO). Established in 1993 as an operationally independent, publicly listed subsidiary of Biocon Limited, Syngene has grown to become a world-class scientific solutions partner for a diverse range of industries, including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. The company's core mission is to deliver innovative scientific solutions, offering end-to-end services that span the entire lifecycle of a product, from initial discovery research through clinical development and commercial manufacturing. This integrated model covers both small and large molecules, including advanced modalities like peptides, oligonucleotides, and antibody-drug conjugates (ADCs).

Syngene operates on a global scale with state-of-the-art infrastructure across four primary campuses located in India's key life science hubs—Bangalore, Hyderabad, and Mangalore—and a strategic presence in Baltimore, USA. This network of facilities, qualified to meet international standards set by regulators like the US FDA and EMA, spans over 2.5 million square feet. The scientific foundation of the company is its team of over 8,200 professionals, which includes more than 5,600 highly qualified scientists. This deep pool of talent enables Syngene to function as a trusted thought partner for its clients, driving cutting-edge research and development. The company serves over 400 active clients, including 14 of the top 20 global pharmaceutical companies, with a significant client base in the US, Europe, and Japan. Syngene's long-standing strategic partnerships, such as its 25-year collaboration with Bristol Myers Squibb, underscore its reputation for quality, reliability, and scientific excellence.

Official Website: http://www.syngeneintl.com/

• Q3 FY26 Performance:

• Revenue from Operations: Stood at Rs. 917 Cr, a decline of 3% year-over-year (Y-o-Y).

• Operating EBITDA Margin: Contracted significantly to 23% compared to 30% in Q3 FY25.

• Profit After Tax (PAT): Reported PAT before exceptional items was Rs. 73 Cr, a sharp decrease of 44% Y-o-Y. The PAT margin was 7.8%, down from 13.6% in the prior year's quarter.

• 9M FY26 Performance:

• Revenue from Operations: Grew marginally by 3% Y-o-Y to Rs. 2,702 Cr.

• Operating EBITDA Margin: Declined to 23% from 27% in 9M FY25.

• Profit After Tax (PAT): Reported PAT before exceptional items fell by 22% Y-o-Y to Rs. 227 Cr.

• Balance Sheet Position (as of Dec 31, 2025):

• Shareholders’ Funds: Rs. 47,663 Mn.

• Net Fixed Assets: Rs. 40,494 Mn.

• Net Cash/(Debt): The company holds a net cash position of Rs. 9,019 Mn, indicating a strong and liquid balance sheet.

The recent financial performance shows top-line pressure and significant margin contraction, resulting in a substantial decline in profitability despite a strong balance sheet.

• Integrated CRDMO Platform: Syngene offers a comprehensive, one-stop platform for drug discovery, development, and manufacturing. This integrated capability spans small molecules, large molecules, and novel modalities like ADCs and PROTACs, which is a key differentiator.

• Flexible Collaboration Models: The company provides multiple engagement models to suit client needs, including Dedicated R&D Centers for long-term strategic partnerships, Full-Time Equivalent (FTE) models for evolving projects, Fee-For-Service (FFS) for specific tasks, and outcome-based or risk/reward models.

• Deep Scientific Expertise: The workforce comprises over 5,600 scientists, providing the intellectual capital to handle complex scientific challenges. This talent pool, combined with a track record of over 400 patents held with clients, reinforces its position as a science-led organization.

• Operational and Digital Excellence: Syngene focuses on structured program management, digital integration with AI capabilities, and a robust global supply chain with over 2,800 suppliers. This commitment is supported by a digitized quality management system that successfully cleared 111 client and regulator audits in the last financial year.

Syngene's unique value proposition lies in its fully integrated service platform, diverse and flexible client engagement models, and a deep scientific talent base.

• Three-Pronged Growth Strategy:

• Research Services: Aims to provide end-to-end therapeutic discovery services across multiple technologies, disease areas, and therapeutic modalities.

• Development & Manufacturing (Small Molecules): Focuses on leveraging existing CMC capabilities and commercial manufacturing to become a fully integrated service provider.

• Development & Manufacturing (Large Molecules): Implements a comprehensive strategy to establish a seamless "one-stop-shop" capability from drug discovery to commercial biologics production.

• Historical Growth Metrics (FY16 to FY25):

• Client Base: Grew from over 250 active clients in FY16 to approximately 400 in FY25.

• Infrastructure: Expanded from 0.9 million sq. ft. in March 2016 to over 2.5 million sq. ft. in March 2025.

• Headcount: Nearly tripled from 3,526 employees in FY16 to 8,235 in FY25.

• Strategic Partnerships: The extension of the long-standing partnership with Bristol Myers Squibb (BMS) through to 2035 with a broadened scope is a significant driver for sustained, long-term revenue.

The company's growth is anchored in a clear three-pronged strategy focused on expanding its integrated service offerings, supported by a proven track record of scaling its client base, infrastructure, and talent.

• Expanded BMS Partnership: The recent extension of the collaboration with Bristol Myers Squibb to 2035 not only secures a long-term revenue stream but also broadens the scope of services across the entire drug development lifecycle, creating significant upselling opportunities.

• New Technologies and Capabilities: Syngene is actively investing in new technologies. The commissioning of a commercial-scale facility for liquid-filled hard gelatin capsules and the expansion of advanced chemistry capabilities (catalytic screening and flow chemistry) in Hyderabad open new service lines and improve efficiency.

• Biologics Manufacturing: The acquisition of a biologics manufacturing facility in Baltimore, USA, provides a strategic international presence. This expansion increases total single-use bioreactor capacity to 50,000L, positioning Syngene to capture more business in the high-growth large molecule CDMO market.

• Emerging Biopharma Segment: The share of total revenue from US-based emerging biotech companies has increased from 10% in FY21 to 14% in FY25, indicating a growing opportunity to partner with innovative, smaller firms.

Key opportunities lie in leveraging the long-term BMS contract, capitalizing on new technological capabilities, and aggressively expanding its footprint in the global biologics manufacturing market.

• Significant Infrastructure Expansion: Syngene has more than doubled its infrastructure footprint since 2016, reaching over 2.5 million sq. ft. of world-class R&D and manufacturing facilities.

• Strategic Acquisitions and Expansions:

• Mangalore: Expanded for commercial API manufacturing.

• Hyderabad: Acquired 17 acres of land to support long-term growth in the research business.

• Bangalore: Acquired a multi-modal biologics manufacturing facility from Stelis Biopharma.

• Baltimore, USA: Acquired a state-of-the-art biologics site, increasing total single-use bioreactor capacity for large molecules to 50,000L.

• Global Campus Network: The company operates across four global campuses in Bangalore, Mangalore, Hyderabad, and Baltimore, providing scaled capacity to meet diverse client needs.

Syngene has been in a significant capex cycle, strategically expanding its physical infrastructure and manufacturing capacity, particularly in high-growth areas like biologics and commercial APIs.

• Integrated Service Provider Goal: The central plan is to solidify its position as a fully integrated, end-to-end CRDMO for both small and large molecules, covering the entire chain from discovery to commercial supply.

• Focus on Operational Excellence: The strategy emphasizes driving efficiency, reliability, and speed through continuous improvement initiatives (Six Sigma), digital transformation (AI adoption, Project VEGA), and robust project management.

• Talent Development: A key pillar is building a future-ready organization by nurturing leadership and enhancing scientific skills through initiatives like the Scientific Skills Development Academy.

• ESG Commitment: The company is committed to responsible and sustainable growth, aligning with evolving expectations from clients and investors, as evidenced by its strong ESG ratings from agencies like Sustainalytics and MSCI.

The company's future plans are centered on executing its integrated CRDMO strategy, underpinned by a commitment to operational excellence, talent development, and sustainable business practices.

• Q3 FY26 Margin Contraction: The operating EBITDA margin for the quarter was 23%, a significant decline from 30% in the same quarter of the previous year (Q3 FY25).

• 9M FY26 Margin Performance: For the nine months ended December 31, 2025, the operating EBITDA margin was 23%, down from 27% in the corresponding period of FY25.

• Profitability Impact: This margin compression has directly impacted profitability, with PAT before exceptional items falling 44% Y-o-Y in Q3 and 22% Y-o-Y for the nine-month period.

The company is currently facing significant pressure on its profitability margins, which have contracted notably in the recent reporting periods.

• Structured Risk Management Framework: Syngene employs a formal, enterprise-wide risk management framework to identify, monitor, and mitigate risks.

• Four-Tiered Oversight Structure:

1. Risk Owner: Responsible for the continuous identification, assessment, and monitoring of risks at the operational level.

2. Executive Committee: Reviews enterprise-level risks and oversees the implementation of mitigation plans.

3. Risk Management Committee: Oversees the entire framework, defines risk appetite, and ensures a balance between risk and reward.

4. Board of Directors (BOD): Defines the company’s overall risk tolerance and policy, providing ultimate oversight.

Syngene has a robust, multi-layered risk management framework in place, ensuring that potential risks are systematically identified and addressed from the operational level up to the Board of Directors.

• Awards and Recognition:

• Received a 5S Certification from the Union of Japanese Scientists and Engineers (JUSE) for its Translational & Clinical Research unit, making it the only pharma/biotech organization in India with this recognition.

• Ranked by TIME magazine and Statista amongst the “World’s Best Companies in Sustainable Growth” for 2026, placing it #1 in India and in the global top three in the Pharma and Biotech category.

• Recognized with multiple CDMO Leadership Awards and Biopharma Excellence Awards in 2025.

• ESG Performance:

• Procures 92% of its energy from renewable sources.

• Achieved a 64% Y-o-Y saving in freshwater consumption.

• Holds strong ESG ratings, including a Silver rating from Ecovadis, a 'B' rating from CDP for both Climate Action and Water Security, and an 'A' rating from MSCI.

The company continues to gain external validation for its operational excellence, sustainability practices, and industry leadership through prestigious awards and strong ESG ratings.